Maravai Lifesciences Holdings Inc Cash Flow Conversion Efficiency
Maravai Lifesciences Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Maravai Lifesciences Holdings Inc (MRVI) has a cash flow conversion efficiency ratio of 0.011x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.99 Million) by net assets ($355.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Maravai Lifesciences Holdings Inc (2018–2025)
Cash flow conversion efficiency of Maravai Lifesciences Holdings Inc from 2018 to 2025. This chart illustrates how Maravai Lifesciences Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MRVI stock price for real-time trading data and today's change.
Maravai Lifesciences Holdings Inc Cash Flow Conversion Ratio Explained
Maravai Lifesciences Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Maravai Lifesciences Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maravai Lifesciences Holdings Inc ranked by their cash flow conversion efficiency. Also see MRVI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Evolution Metals & Technologies Corp. Common Stock
NASDAQ:EMAT
|
0.491x |
|
TTW Public Company Limited
BK:TTW-R
|
0.043x |
|
He Bei Cheng De LoLo Co Ltd
SHE:000848
|
0.076x |
|
Norconsult ASA
OL:NORCO
|
-0.019x |
|
Flow Traders BV
AS:FLOW
|
-1.463x |
|
OMH SCIENCE Group Co Ltd
SHE:300486
|
-0.100x |
|
Hunan Valin Wire & Cable Co Ltd
SHE:001208
|
-0.004x |
|
Luoyang Longhua Heat Trans Energy
SHE:300263
|
0.024x |
Annual Cash Flow Conversion Efficiency for Maravai Lifesciences Holdings Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Maravai Lifesciences Holdings Inc from 2018 to 2025. Review MRVI free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $372.71 Million | $-57.57 Million | -0.154x | -1294.40% |
| 2024-12-31 | $577.21 Million | $7.46 Million | 0.013x | -91.91% |
| 2023-12-31 | $789.88 Million | $126.22 Million | 0.160x | -73.01% |
| 2022-12-31 | $905.24 Million | $535.98 Million | 0.592x | -12.39% |
| 2021-12-31 | $545.36 Million | $368.57 Million | 0.676x | -31.28% |
| 2020-12-31 | $154.75 Million | $152.19 Million | 0.983x | +489.82% |
| 2019-12-31 | $144.63 Million | $24.11 Million | 0.167x | +13368.86% |
| 2018-12-31 | $148.02 Million | $-186.00K | -0.001x | -- |
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products fo… Read more